STOCK TITAN

Celcuity Inc - CELC STOCK NEWS

Welcome to our dedicated news page for Celcuity (Ticker: CELC), a resource for investors and traders seeking the latest updates and insights on Celcuity.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celcuity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celcuity's position in the market.

Rhea-AI Summary
Celcuity Inc. (Nasdaq: CELC) received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC). They also entered into a clinical trial collaboration and supply agreement with Bayer AG to provide Nubeqa® (darolutamide) for a planned Phase 1b/2 clinical trial. Additionally, they raised $50 million in a private placement sale of equity. The VIKTORIA-1 Phase 3 trial evaluating gedatolisib in combination with fulvestrant and palbociclib for HR+, HER2- advanced breast cancer remains on track, with initial data expected in 2024 and 2025. The CELC-G-201 Phase 1b/2 clinical trial for metastatic castration resistant prostate cancer is set to activate trial sites in 2024 and report initial data in 2025. Third quarter financial results showed an increase in operating expenses and a net loss of $18.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
-
Rhea-AI Summary
Celcuity Inc. will release its financial results for the third quarter 2023 on November 13, 2023. A webcast/teleconference will be held at 8:00 a.m. Eastern Time on the same day to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
-
Rhea-AI Summary
Celcuity Inc. (Nasdaq: CELC) announced that Brian Sullivan, Chairman, CEO, and Co-founder, will present at the Stifel 2023 Healthcare Conference on November 14 and participate in a fireside chat at the Jefferies London Healthcare Conference on November 16.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.35%
Tags
conferences
Rhea-AI Summary
Celcuity Inc. announces a private placement to sell securities, expected to result in $50 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.38%
Tags
none
-
Rhea-AI Summary
Celcuity Inc. to host Virtual Science Day for analysts and investors on September 21, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
conferences
-
Rhea-AI Summary
Celcuity Inc. announces clinical trial collaboration and supply agreement with Bayer AG for Phase 1b/2 trial of gedatolisib and Nubeqa in mCRPC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
Rhea-AI Summary
Celcuity receives FDA clearance for IND submission of gedatolisib in combination with darolutamide for the treatment of mCRPC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
-
Rhea-AI Summary
Celcuity Inc. reports positive results from Phase 1b study of gedatolisib in treatment-naïve advanced breast cancer. Median progression free survival (PFS) was 48.6 months. Phase 3 VIKTORIA-1 trial recruiting patients at nearly 200 sites in 20 countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
-
Rhea-AI Summary
Celcuity Inc. will release its financial results for Q2 2023 on August 10, 2023, and host a webcast/teleconference to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences
Celcuity Inc

Nasdaq:CELC

CELC Rankings

CELC Stock Data

557.60M
14.06M
19.37%
53.67%
6.12%
Medical Laboratories
Health Care and Social Assistance
Link
United States
Minneapolis

About CELC

celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.